Recently, the phase III study Pancreatic Cancer Olaparib Ongoing (POLO) evaluated the role of maintenance olaparib, a PARP inhibitor, in patients with BRCA1 and BRCA2 germline pathogenic mutations who were not progressed after 16 weeks of first-line platinum based chemotherapy, reporting an improved progression free survival (PFS) in comparison to the placebo group, while no benefit in overall survival (OS) was observed [17]. This evidence concerns the gene PARP1 and familial pancreatic carcinoma.